Clinical
RSSArticles
-
Research Shows High Levels of Interest for OTC Medication Abortion
A recent study that is part of a long-term research project about the possibility of OTC medication abortion found a high interest, among abortion patients, in accessing OTC abortion pills.
-
An Over-the-Counter Birth Control Pill Could Be a Game-Changer
The application for the first OTC birth control pill in the United States marks a new chapter in the ever-changing reproductive healthcare environment of 2022. In June, Perrigo Company announced its HRA Pharma arm submitted an application to the FDA to approve its progestin-only daily birth control pill, Opill, for OTC status.
-
Report: Patients Sicker Now Than Before the COVID-19 Pandemic
Delayed care also driving longer lengths of stay, price increases for labor and supplies.
-
Researchers Explore Connections Between Epilepsy and Postpartum Anxiety, Depression
Clinicians should monitor for signs of depression among patients with epilepsy who are pregnant or patients who are thinking about conceiving.
-
Text Messages Boosted Pediatric Flu Vaccination Rates
Personalized, interactive, educational reminders led parents to bring children for the second shot faster and at a higher rate.
-
Using Biomarkers to Predict Traumatic Brain Injury Outcomes
Measuring proteins on day of injury could help improve current predictive models.
-
FDA Finalizes Rule on Over-the-Counter Hearing Aids
Affordable devices could be available for sale later this year.
-
What Do You Think Happened?
You are asked to interpret the tracing in the figure without the benefit of any history. What do you think happened? How acute are these findings?
-
Baricitinib Tablets (Olumiant)
Baricitinib is the first FDA-approved systemic treatment of alopecia areata.
-
Outcomes of COVID-19-Associated Acute Myocarditis
In a review of COVID-19-associated acute myocarditis, investigators learned it is a rare complication that can occur without concomitant pneumonia, and frequently presents as cardiogenic shock. With supportive therapy, the short-term mortality rate is low.